[ad_1]
Healthcare Provider Partners With Merck For Clinical Research Of New COVID-19 Antiviral Treatments
SAN FRANCISCO, September 30, 2021– (BUSINESS WIRE) – Carbon Health, a leading national healthcare provider, today unveiled Carbon for Research, a clinical trial research program that has partnered with therapeutic companies to conduct cutting-edge research for clinical trials focused on medical devices, diagnostics, therapeutics and vaccines. Through Carbon for Research, Carbon Health continues its mission of providing high quality health care to all by advancing health care for diverse populations.
As part of this national program, Merck, a multinational pharmaceutical company, selected Carbon Health to participate in two international double-blind phase III clinical trials to test the effectiveness of a new COVID-19 antiviral treatment pill, molnupiravir for both treatment and prophylaxis. indications.
Carbon for Research leverages the company’s integrated technology platform, nationwide clinical access points, a diverse patient population, and a sophisticated central operating model. The program has completed several studies and covers all aspects of clinical trial research development and execution, including identifying Carbon Health study sites based on partner needs, budgeting, procurement markets, study training, operations, regulatory oversight and an in-house EHR technology platform that enables analysts to efficiently generate targeted screening mechanisms for study teams to review patient data and recruit effectively. Carbon Health’s omnichannel care model enables research partners to reach patients through 90 in-person clinics in 14 states, home care (including remote patient monitoring), telehealth, and CarePods. By enabling partners to reach a wide range of patients through a variety of access points, Carbon Health supports increasing the racial, socio-economic and geographic diversity of its partners’ clinical studies. This model allows studies to be conducted more efficiently, quickly and cost effectively while minimizing errors and lowering traditional barriers.
Carbon Health has partnered with Merck in two double-blind clinical trials to test the effectiveness of a new COVID-19 antiviral treatment pill, molnupiravir. The first treatment trial is based in Los Angeles and aims to study whether molnupiravir decreases disease severity in high-risk, unvaccinated patients who have tested positive for COVID-19. Based in San Diego and the Bay Area, the second prophylaxis trial evaluates the effectiveness of molnupiravir in preventing transmission to those who have been exposed to COVID-19 but are not yet infected. To enroll in the study, the patient must be unvaccinated and live with a symptomatic COVID-positive patient.
“The COVID-19 pandemic has proven that new therapies and diagnostics can be developed and launched quickly and safely through strategic partnerships, better access to patient populations, timely resources and streamlined business models,” said said Dr. Aaron Weinberg, medical director of program development. & National Director of Carbon for Research. “However, many clinical trials are not inclusive enough and, therefore, are unable to reflect diverse healthcare needs. Carbon for Research provides a new end-to-end solution while driving patient recruitment. diversified in clinical research to ensure that future therapies and interventions are safe and effective for all in the population.
In addition to driving advances in healthcare through its clinical trials program, during the pandemic, Carbon Health led several public health initiatives to increase access to healthcare and help patients manage their long-term symptoms around COVID-19. Carbon Health has launched a fully integrated HIPAA-compliant solution to enable businesses to securely comply with current and future COVID vaccination mandates by collecting, storing and facilitating reporting of sensitive immunization and testing information. employees. The company has administered more than 1.4 million COVID-19 tests and 1.5 million COVID-19 vaccines and has launched programs such as COVID Positive Care to provide comprehensive care, monitoring and education for COVID-patients. 19 and COVID Ready to help businesses and employees get back to work safely. Carbon Health’s commitment to providing COVID-19 care, vaccines and ongoing clinical research underscores its goal of creating a long-term care relationship with patients through which it provides care when and where patients need it. most needed.
To register for a clinical trial or inquire about partnerships with Carbon for Research, contact [email protected] or call 818-208-8574.
About Carbon Health
Carbon Health is a leading national healthcare provider with a mission to provide high quality healthcare to everyone. Carbon Health provides accessible primary and urgent care to nearly two-thirds of the United States. Leveraging its unique technology platform, Carbon Health offers its patients omnichannel which, designed to meet patients where they are by providing care through a variety of access points, including in-person clinics, home care, equipment, on-site care by employer and virtually via the Carbon Health app. Carbon Health also provides value-based care to partner companies across a wide range of industries, including academia, sports, entertainment, biotechnology, and travel.
Founded in 2015, Carbon Health is headquartered in San Francisco and is backed by Atreides, Blackstone Horizon, Dragoneer Investment Group, Brookfield Technology Partners (BTP), Fifth Wall, Lux Capital, Silver Lake Waterman, DCVC and Builders VC. To access Carbon Health, download the app (iTunes or Google Play) or visit carbonhealth.com.
About Merck
For more than 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, providing drugs and vaccines for many of the world’s most difficult diseases as part of our mission to save and improve lives. We demonstrate our commitment to patients and the health of the population by increasing access to health care through broad policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten humans and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company. in the world. For more information, visit www.merck.com and contact us on Twitter, Facebook, Instagram, YouTube and LinkedIn.
See the source version on businesswire.com: https://www.businesswire.com/news/home/202109300005270/en/
Contacts
Lindsey Whitehouse
[email protected]
Melissa Moody
[email protected]
[ad_2]
Source link
